Search Results

Business

NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary

NeoGenomics, Inc. announced the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata and the departure of former President of Inivata Dr. Clive Morris.

May 9, 2022

·

8 min read

Business

Inivata Appoints David Eberhard MD, PhD as Chief Medical Officer

Inivata Appoints David Eberhard MD, PhD as Chief Medical Officer.

December 13, 2021

·

3 min read

Deals

Inivata to be Acquired by NeoGenomics

Inivata, a leader in liquid biopsy, today announces that NeoGenomics, Inc (NASDAQ: NEO.), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has agreed to acquire Inivata.

May 5, 2021

·

5 min read

BioMidwest

NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022

NeoGenomics, Inc. announces that its liquid biopsy focused subsidiary Inivata Limited, alongside collaborators, will present new data on its RaDaR™ assay for the detection of minimal residual disease and recurrence at the European Society for Medical Oncology Congress, taking place September 9th-13th, 2022.

September 7, 2022

·

8 min read

Bio NC

Inivata and Collaborators to Present New Data to Support the Application of RaDaR™ MRD Assay Across Tumor Types at ESMO Congress 2022

Inivata, a leader in liquid biopsy, alongside collaborators, will present new data on its RaDaR™ assay for the detection of minimal residual disease and recurrence at the European Society for Medical Oncology Congress, taking place on 9-13 September 2022.

September 7, 2022

·

4 min read

Business

Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy Assays

Inivata, a leader in liquid biopsy, announced a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivata’s liquid biopsy assays, InVisionFirst®-Lung and RaDaR™ in two separate studies.

October 19, 2021

·

3 min read

Bio NC

Inivata and Collaborators Publish New Data on RaDaR™ MRD Assay at AACR 2022

Inivata, a leader in liquid biopsy, today unveils new data at the American Association for Cancer Research (AACR) Annual Meeting further demonstrating the potential of its RaDaR assay for the detection of minimal residual disease (MRD) and recurrence.

April 11, 2022

·

3 min read

Business

Inivata Announces Collaboration with F-star Therapeutics for the use of RaDaRTM Assay

Inivata, a leader in liquid biopsy, announced a collaboration with F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, for the use of Inivata’s RaDaR technology.

May 25, 2021

·

2 min read

Bio NC

Inivata and Collaborators Publish Clinical Validation Data for RaDaR™ Assay in Non-Small Cell Lung Cancer

Inivata, a leader in liquid biopsy, announced the publication of new data in support of its RaDaR™ liquid biopsy test in patients with early-stage non-small cell lung cancer.

March 17, 2022

·

3 min read

Bio NC

Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR™ in Head and Neck Squamous Cell Carcinoma

Inivata, a leader in liquid biopsy, announced clinical validation data for its RaDaRTM liquid biopsy test in head and neck squamous cell carcinoma.

February 11, 2022

·

3 min read